Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow

Impact · against what's priced in

The article is not a catalyst for Cencora. It reaffirms general strengths like operating margins and cash flow that the market has already factored into the current valuation.

COR+0.00

Already priced in

The price assumes

Adjusted EPS growth of 12% to 14% and consolidated operating income growth

The author's focus on positive operating cash flow and improved operating margins simply confirms the growth targets the market is already paying for.

What COR's price assumes · Sep 13

• pharmaceuticals
• healthcare
• dividends
• regulation
• COR
• supply chain
• tariffs

Search tags